mProX™ Human RXFP3 Stable Cell Line

Product Information

Target Protein

RXFP3

Target Family

Relaxin Family

Target Protein Species

Human

Host Cell Type

SH-SY5Y; CHO-K1; HEK293

Target Classification

GPCR Cell Lines

Target Research Area

CNS Research

Related Diseases

Schizotypal Personality Disorder; Chromosome 5P13 Duplication Syndrome

Gene ID

51289

UniProt ID

Q9NSD7

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

RNL3/relaxin-3 has a receptor called RXFP3. The ligand's binding prevents cAMP buildup. Relaxin-3 is the primary ligand for RXFP3. According to the current research, relaxin-3 is a neurohormone that primarily regulates central nervous system function, including the regulation of reaction, upkeep of arousal, and cognitive function. Additionally, the activation of RXFP1 and RXFP3/4 by H3 relaxin results in various intracellular responses in vitro. Cell signaling processes related to the relaxin-family receptors have been studied in various cell lines transfected with the human receptors. According to reports, RXFP3 and RXFP4 couple to the inhibitory Gαi/o-protein system in CHO cells. Receptor activation causes these G proteins to be sequestered, adenylate cyclase (AC) to be inhibited, and cAMP to accumulate as a result. The customized RXFP3 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human RXFP3 Stable Cell Line (S01YF-0923-KX28). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Lena (Verified Customer)

What's the incubation time and other information of this product? Sep 15 2022

chat Sherry Smith (Creative Biolabs Scientific Support)

Rrefer to the product's datasheet found on the product's details webpage. Sep 15 2022

chat Bob (Verified Customer)

What's assay conditions for my cell product? Mar 09 2023

chat Sherry Smith (Creative Biolabs Scientific Support)

The ideal test conditions are unknown in the absence of the reference agonist. We can, however, provide a starting point to use until an agonist is found that might then be utilized to improve assay conditions. Mar 09 2023

Published Data

Fig.1 Discovery of RXFP3 as a possible controller for GIT2.

As control cells were also overexpressed via transient transfection with an empty vector, RXFP3 was overexpressed in SH-SY5Y and HEK293 cells at 1 and 2 g. A loading control was performed using actin. Following overexpression of RXFP3 in both cell types, a particular increase in GIT2 expression was observed.

Ref: van Gastel, Jaana, et al. "The RXFP3 receptor is functionally associated with cellular responses to oxidative stress and DNA damage." Aging (Albany NY) 11.23 (2019): 11268.

Pubmed: 31794429

DOI: 10.18632/aging.102528

Research Highlights

A class A G protein-coupled receptor family member is the relaxin/insulin-like family peptide receptor 3 (RXFP3). The brain is the primary site of expression for RXFP3 and relaxin-3, which play critical roles in the control of hunger, energy metabolism, endocrine balance, and emotional processing. As a result, it is suggested as a possible therapeutic target for a number of central nervous system illnesses.
Lin, Guangyao, et al. "High-throughput screening campaign identified a potential small molecule RXFP3/4 agonist." Molecules 26.24 (2021): 7511.
Pubmed: 34946593 DOI: 10.3390/molecules26247511

The most prevalent eating disorder is binge-eating disorder. Several neuropeptides, such as relaxin-3 (RLN3), which promotes food intake in rats by activating the relaxin-family peptide-3 receptor (RXFP3), play significant roles in the control of feeding behavior.
Kania, Alan, et al. "RLN3/RXFP3 signaling in the PVN inhibits magnocellular neurons via M-like current activation and contributes to binge eating behavior." Journal of Neuroscience 40.28 (2020): 5362-5375.
Pubmed: 32532885 DOI: 10.1523/JNEUROSCI.2895-19.2020